Dalton Pharma Services, a North American pharmaceutical cGMP contract manufacturing company, has declared the signing of a drug development and manufacturing services agreement with Oryn Therapeutics, an American biotechnology firm committed to the clinical development of novel and affordable drugs to address unmet medical needs in autoimmunity, inflammation and infectious diseases.
Under the signed agreement, Dalton will provide drug development and cGMP aseptic liquid filling of ORTD-1 in glass vials which will be used for Phase-1 clinical studies of ORTD-1 by the third quarter of this year.
ORTD-1 is a first-in-class drug for treatment of rheumatoid arthritis (RA). RA affects about one percent of the population worldwide. It is the third most common type of arthritis and causes more disability than any other condition, including heart disease, diabetes and back/spine problems.
Due to its severely debilitating nature in advanced stages, it accounts for 22 percent of all deaths from arthritis and other rheumatic conditions. ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after only nine days of treatment. The remission is long lasting (two to three months) after treatment is discontinued.
(Source: Dalton Pharma Services)
